Johnson & Johnson Reveals Promising Phase 3 Results for Bispecific Myeloma Therapy
STOCKHOLM, Sweden, June 13, 2026 Johnson & Johnson has announced groundbreaking results from the pivotal Phase 3 MonumenTAL-3 clinical...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
STOCKHOLM, Sweden, June 13, 2026 Johnson & Johnson has announced groundbreaking results from the pivotal Phase 3 MonumenTAL-3 clinical...
CAMBRIDGE, Massachusetts, ROTTERDAM, Netherlands, and SHANGHAI, China, June 14, 2026 Harbour BioMed has secured a major legal victory in...
